FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1986362009> ?p ?o ?g. }

• W1986362009 endingPage "370" @default.
• W1986362009 startingPage "360" @default.
• W1986362009 abstract "Background Whether treatment with adenosine receptor antagonists such as theophylline can prevent contrast-induced acute kidney injury (AKI) remains controversial. Study Design We conducted a meta-analysis of randomized controlled trials using MEDLINE (1966 to July 2011), EMBASE (1980 to July 2011), Web of Science (1986 to July 2011), and the Cochrane Central Register of Controlled Trials (1996 to July 2011), without language restriction. Setting & Population Patients undergoing contrast procedures. Selection Criteria for Studies Randomized controlled trials assessing adenosine antagonists versus control for prevention of contrast-induced AKI. Intervention Adenosine antagonists with or without N-acetylcysteine versus control with or without N-acetylcysteine. Outcomes Contrast-induced AKI, change in serum creatinine level, requirement of dialysis, and in-hospital mortality. Results 16 trials (1,412 participants) were included. Theophylline significantly decreased the risk of contrast-induced AKI (13 trials, 1,222 patients; risk ratio, 0.48; 95% CI, 0.26-0.89; P = 0.02; I2 = 45%) and had a protective effect on the absolute change in serum creatinine concentration (13 trials, 1,170 patients; standardized mean difference, −0.31 mg/dL; 95% CI, −0.50 to −0.11; P = 0.002; I2 = 60%). Meta-regression showed a significant relation between the relative risk of contrast nephropathy and baseline serum creatinine level or Jadad score. No clear effects of treatment on risk of dialysis and in-hospital mortality were identified. Limitations Power to assess clinical end points was limited. Conclusions Theophylline treatment significantly reduced the incidence of contrast-induced AKI and had a modest improvement on kidney function after contrast exposure in the general population. However, beneficial effects of theophylline were not observed in patients with high baseline creatinine values (serum creatinine ≥1.5 mg/dL). In addition, the long-term effect of this agent on more clinically important outcomes was not established. Future large-scale high-quality multicenter trials in participants with different underlying risks of contrast-induced AKI and that incorporate the evaluation of clinically relevant outcomes are required. Whether treatment with adenosine receptor antagonists such as theophylline can prevent contrast-induced acute kidney injury (AKI) remains controversial. We conducted a meta-analysis of randomized controlled trials using MEDLINE (1966 to July 2011), EMBASE (1980 to July 2011), Web of Science (1986 to July 2011), and the Cochrane Central Register of Controlled Trials (1996 to July 2011), without language restriction. Patients undergoing contrast procedures. Randomized controlled trials assessing adenosine antagonists versus control for prevention of contrast-induced AKI. Adenosine antagonists with or without N-acetylcysteine versus control with or without N-acetylcysteine. Contrast-induced AKI, change in serum creatinine level, requirement of dialysis, and in-hospital mortality. 16 trials (1,412 participants) were included. Theophylline significantly decreased the risk of contrast-induced AKI (13 trials, 1,222 patients; risk ratio, 0.48; 95% CI, 0.26-0.89; P = 0.02; I2 = 45%) and had a protective effect on the absolute change in serum creatinine concentration (13 trials, 1,170 patients; standardized mean difference, −0.31 mg/dL; 95% CI, −0.50 to −0.11; P = 0.002; I2 = 60%). Meta-regression showed a significant relation between the relative risk of contrast nephropathy and baseline serum creatinine level or Jadad score. No clear effects of treatment on risk of dialysis and in-hospital mortality were identified. Power to assess clinical end points was limited. Theophylline treatment significantly reduced the incidence of contrast-induced AKI and had a modest improvement on kidney function after contrast exposure in the general population. However, beneficial effects of theophylline were not observed in patients with high baseline creatinine values (serum creatinine ≥1.5 mg/dL). In addition, the long-term effect of this agent on more clinically important outcomes was not established. Future large-scale high-quality multicenter trials in participants with different underlying risks of contrast-induced AKI and that incorporate the evaluation of clinically relevant outcomes are required." @default.
• W1986362009 created "2016-06-24" @default.
• W1986362009 creator A5001122836 @default.
• W1986362009 creator A5016903166 @default.
• W1986362009 creator A5025974550 @default.
• W1986362009 creator A5041162178 @default.
• W1986362009 creator A5057458570 @default.
• W1986362009 creator A5064304246 @default.
• W1986362009 date "2012-09-01" @default.
• W1986362009 modified "2023-09-27" @default.
• W1986362009 title "Effect of Theophylline on Prevention of Contrast-Induced Acute Kidney Injury: A Meta-analysis of Randomized Controlled Trials" @default.
• W1986362009 cites W1487297692 @default.
• W1986362009 cites W1660053632 @default.
• W1986362009 cites W1913363311 @default.
• W1986362009 cites W1970052157 @default.
• W1986362009 cites W1973683620 @default.
• W1986362009 cites W1973914781 @default.
• W1986362009 cites W1978463699 @default.
• W1986362009 cites W1984903215 @default.
• W1986362009 cites W1986215651 @default.
• W1986362009 cites W1993550716 @default.
• W1986362009 cites W1999584733 @default.
• W1986362009 cites W2024155525 @default.
• W1986362009 cites W2036321687 @default.
• W1986362009 cites W2041228076 @default.
• W1986362009 cites W2047474179 @default.
• W1986362009 cites W2053697714 @default.
• W1986362009 cites W2067360029 @default.
• W1986362009 cites W2068415104 @default.
• W1986362009 cites W2068746864 @default.
• W1986362009 cites W2074497010 @default.
• W1986362009 cites W2075412580 @default.
• W1986362009 cites W2076972259 @default.
• W1986362009 cites W2077035032 @default.
• W1986362009 cites W2085414000 @default.
• W1986362009 cites W2095593855 @default.
• W1986362009 cites W2097091478 @default.
• W1986362009 cites W2100288509 @default.
• W1986362009 cites W2108116635 @default.
• W1986362009 cites W2109105073 @default.
• W1986362009 cites W2110325271 @default.
• W1986362009 cites W2115892605 @default.
• W1986362009 cites W2123861459 @default.
• W1986362009 cites W2127911797 @default.
• W1986362009 cites W2135287442 @default.
• W1986362009 cites W2143687264 @default.
• W1986362009 cites W2151935316 @default.
• W1986362009 cites W2154563701 @default.
• W1986362009 cites W2162176442 @default.
• W1986362009 cites W2170521505 @default.
• W1986362009 cites W2327454703 @default.
• W1986362009 cites W2461455856 @default.
• W1986362009 cites W4211164073 @default.
• W1986362009 cites W4234395934 @default.
• W1986362009 cites W4239172270 @default.
• W1986362009 cites W4245191076 @default.
• W1986362009 cites W4250393049 @default.
• W1986362009 doi "https://doi.org/10.1053/j.ajkd.2012.02.332" @default.
• W1986362009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22516682" @default.
• W1986362009 hasPublicationYear "2012" @default.
• W1986362009 type Work @default.
• W1986362009 sameAs 1986362009 @default.
• W1986362009 citedByCount "54" @default.
• W1986362009 countsByYear W19863620092012 @default.
• W1986362009 countsByYear W19863620092013 @default.
• W1986362009 countsByYear W19863620092014 @default.
• W1986362009 countsByYear W19863620092015 @default.
• W1986362009 countsByYear W19863620092016 @default.
• W1986362009 countsByYear W19863620092017 @default.
• W1986362009 countsByYear W19863620092018 @default.
• W1986362009 countsByYear W19863620092019 @default.
• W1986362009 countsByYear W19863620092020 @default.
• W1986362009 countsByYear W19863620092021 @default.
• W1986362009 countsByYear W19863620092022 @default.
• W1986362009 countsByYear W19863620092023 @default.
• W1986362009 crossrefType "journal-article" @default.
• W1986362009 hasAuthorship W1986362009A5001122836 @default.
• W1986362009 hasAuthorship W1986362009A5016903166 @default.
• W1986362009 hasAuthorship W1986362009A5025974550 @default.
• W1986362009 hasAuthorship W1986362009A5041162178 @default.
• W1986362009 hasAuthorship W1986362009A5057458570 @default.
• W1986362009 hasAuthorship W1986362009A5064304246 @default.
• W1986362009 hasConcept C126322002 @default.
• W1986362009 hasConcept C134018914 @default.
• W1986362009 hasConcept C136524200 @default.
• W1986362009 hasConcept C159641895 @default.
• W1986362009 hasConcept C168563851 @default.
• W1986362009 hasConcept C2776478404 @default.
• W1986362009 hasConcept C2778095195 @default.
• W1986362009 hasConcept C2778569047 @default.
• W1986362009 hasConcept C2779978075 @default.
• W1986362009 hasConcept C2780306776 @default.
• W1986362009 hasConcept C2780400711 @default.
• W1986362009 hasConcept C2780472472 @default.
• W1986362009 hasConcept C2781184683 @default.
• W1986362009 hasConcept C44249647 @default.
• W1986362009 hasConcept C500558357 @default.
• W1986362009 hasConcept C555293320 @default.

• next